Original Research
Published on 13 May 2026
Sex-specific reporting patterns and onset timing of immune-related adverse events associated with nivolumab and pembrolizumab: a dual-database pharmacovigilance analysis
in Cancer Immunity and Immunotherapy
- 154 views